

Cover Story
By Alexandria Carolan and Paul Goldberg
Budget increases in 2020 enabled NCI to boost funding for research project grants, pushing the payline up by two percentage points from last year's level.
By Matthew Bin Han Ong
In Brief


Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for September 2020
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- No need for a speculum? A new era of HPV screening
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally













